LC
ZVRA icon

Lindbrook Capital’s Zevra Therapeutics ZVRA Stock Holding History

Lindbrook Capital’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-250
Closed -$3K – 1556
2019
Q3 		$3K Buy
250
+62
+33% +$1.12K ﹤0.01% 1220
2019
Q2 		$5K Hold
188
– – ﹤0.01% 1074
2019
Q1 		$5K Hold
188
– – ﹤0.01% 1090
2018
Q4 		$5K Buy
+188
New +$7.61K ﹤0.01% 1034

Other funds holding ZVRA

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.51B AUM 33.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RFN
RDA Financial Network Akron, Iowa $459M AUM 24.58% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Lindbrook Capital's ZVRA Position: Q4 2019 in Review

Lindbrook Capital sold out of Zevra Therapeutics (ZVRA) in Q4 2019, closing a stake of 250 shares — an estimated $3K sold.

Lindbrook Capital first reported a position in ZVRA in Q4 2018 and held it in 4 quarters. The position peaked at $5K in Q2 2019. 27 funds tracked by Wall St. Rank hold ZVRA as of Q4 2019.

  • Lindbrook Capital reported no remaining Zevra Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Lindbrook Capital sold 250 Zevra Therapeutics shares in Q4 2019, an estimated $3K.
  • Lindbrook Capital first reported a position in Zevra Therapeutics in Q4 2018 and held it in 4 quarters.
  • Lindbrook Capital's Zevra Therapeutics position peaked at $5K in Q2 2019.
  • 27 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q4 2019.

Based on Lindbrook Capital's 13F filing for Q4 2019, filed 27 Jan 2020.